ClassID:

96952

C07K14/522 - CPC Classification

Classification description:

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons; Chemokines Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC

Recent Application in this class:
#1
20260152576
2026-06-04

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

#2
20260125434
2026-05-07

CXCL-BPI FUSION PROTEIN AND USE THEREOF

#3
20260085132
2026-03-26

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

#4
20260078158
2026-03-19

COMPOSITIONS COMPRISING CXCL10-DERIVED PEPTIDES AND METHODS OF USE THEREOF

#5
20260035485
2026-02-05

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

#6
20260028429
2026-01-29

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

#7
20260022152
2026-01-22

CHEMOKINE BIOLOGICS FOR TREATING INFLAMMATION-RELATED DISEASES AND DISORDERS

#8
20250326808
2025-10-23

TREATMENT OF THE CORNEAL ENDOTHELIUM

#9
20250302921
2025-10-02

REDUCING THE RISK OF MAJOR ADVERSE CARDIAC EVENTS

#10
20250302920
2025-10-02

REDUCING THE RISK OF MAJOR ADVERSE CARDIAC EVENTS

#11
20250288662
2025-09-18

MULTIVALENT DISPLAY ON ENVELOPED PARTICLES WITH HUMAN OLIGOMERIZATION DOMAINS

#12
20250288628
2025-09-18

MUTANT E1A ANTAGONIZING UBIQUITINATION-MEDIATED DEGRADATION AND ITS USE IN THE PREPARATION OF POTENTIATED ONCOLYTIC ADENOVIRUSES AND IMMUNE POTENTIATORS

#13
20250251405
2025-08-07

Atomic Description of Immune Complex that Causes Heparin-Induced Thrombocytopenia

#14
20250230262
2025-07-17

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

#15
20250210128
2025-06-26

COMPUTER-IMPLEMENTED DESIGN OF PEPTIDE:RECEPTOR SIGNALING COMPLEXES FOR ENHANCED CHEMOTAXIS

#16
20250051798
2025-02-13

RNA CONSTRUCT

#17
20250002549
2025-01-02

CLEAVABLE ACTIVATORS OF CXCR3 AND METHODS OF USE

#18
20240360418
2024-10-31

METHODS FOR REDUCING ELEVATED GLUCOSE LEVELS

#19
20240241132
2024-07-18

Atomic description of immune complex that causes heparin-induced thrombocytopenia

#20
20240228669
2024-07-11

A CONJUGATE, COMPOSITION AND METHOD FOR NONCOVALENT ANTIBODY CATENATION THAT INCREASES ANTIGEN-BINDING AVIDITY OF AN ANTIBODY IN PROPORTION TO THE DENSITY OF A TARGET ANTIGEN

#21
20240175052
2024-05-30

Adenovirus armed with bispecific T cell activator

#22
20240150722
2024-05-09

GENETICALLY MODIFIED STEM CELLS

#23
20240132625
2024-04-25

A CONJUGATE, COMPOSITION AND METHOD FOR NONCOVALENT ANTIBODY CATENATION THAT INCREASES ANTIGEN-BINDING AVIDITY OF AN ANTIBODY IN PROPORTION TO THE DENSITY OF A TARGET ANTIGEN

#24
20230416308
2023-12-28

ENCAPSULATED RNA REPLICONS AND METHODS OF USE

#25
20230406899
2023-12-21

PRODUCTS AND METHODS FOR THE DIAGNOSIS AND DIFFERENTIATION OF HEPARIN-INDUCED THROMBOCYTOPENIA FROM VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA AND NON-HEPARIN-INDUCED THROMBOCYTOPENIA

#26
20230377764
2023-11-23

METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO IMMUNOTHERAPEUTIC ANTIBODIES

#27
20230364216
2023-11-16

LENTIVIRAL VECTORS ENABLING ROUTING ANTIGENS TO MHC-II PATHWAY AND INDUCING CD4+ AND CD8+ T-CELL RESPONSES IN A HOST

#28
20230287598
2023-09-14

HUMANIZED ANTIBODIES WITH ULTRALONG COMPLEMENTARY DETERMINING REGIONS

#29
20230265150
2023-08-24

A FUSION PROTEON OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1) AND INTERLEUKIN-2 (IL-2) AND APPLICATIONS THEREOF

#30
20230184745
2023-06-15

Screening method for effective target - E3 ligase combinations

#31
20230160908
2023-05-25

Atomic description of immune complex that causes heparin-induced thrombocytopenia

#32
20220339253
2022-10-27

REDUCING THE RISK OF MAJOR ADVERSE CARDIAC EVENTS

#33
20220326256
2022-10-13

Methods of prognosis and treatment

#34
20220145262
2022-05-12

Genetically modified stem cells

#35
20220072084
2022-03-10

THERAPEUTIC NANOCONJUGATES AND USES THEREOF

#36
20220056102
2022-02-24

MULTI-FUNCTIONAL FUSION PROTEINS AND USES THEREOF

#37
20220041724
2022-02-10

PLASMID CONSTRUCTS FOR TREATING CANCER AND METHODS OF USE

#38
20210388048
2021-12-16

Cleavable activators of CXCR3 and methods of use

#39
20210355449
2021-11-18

Genetically modified stem cells

#40
20210300981
2021-09-30

COMPOSITIONS AND METHODS FOR COMBATING MULTIDRUG-RESISTANT BACTERIA

#41
20210284754
2021-09-16

HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS

#42
20210052708
2021-02-25

Treatment of infection by human enterovirus D68

#43
20200405772
2020-12-31

Methods for reducing elevated glucose levels

#44
20200353047
2020-11-12

Using nucleic acids encoding NAP-2 polypeptides to improve cardiac function

#45
20200283731
2020-09-10

Genetically modified stem cells

#46
20200239599
2020-07-30

Humanized antibodies with ultralong complementary determining regions

#47
20200216859
2020-07-09

Adenovirus armed with bispecific T cell activator

#48
20200157221
2020-05-21

Oncolytic viral delivery of therapeutic polypeptides

#49
20200123228
2020-04-23

Methods of treating cancer with placenta growth factor peptide linked to immunotherapeutic antibodies

#50
20200016243
2020-01-16

TREATMENT OF INFECTION BY HUMAN ENTEROVIRUS D68

#51
20200003786
2020-01-02

Atomic description of immune complex that causes heparin-induced thrombocytopenia

#52
20190307821
2019-10-10

METHODS AND COMPOSITIONS FOR CANCER THERAPY

#53
20190271709
2019-09-05

Methods of prognosis and treatment

#54
20190270788
2019-09-05

CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS

#55
20190218518
2019-07-18

Treating diabetes with genetically modified beta cells

#56
20190144872
2019-05-16

Generating targeted sequence diversity in fusion proteins

#57
20190127718
2019-05-02

SUPPRESSION OF CANCER

#58
20190092827
2019-03-28

Trapped Chemokine Variants as Therapeutic Agents for Inflammation-Related Diseases Including Infections, Diabetes, and Cancer

#59
20190048082
2019-02-14

Oncolytic viral delivery of therapeutic polypeptides

#60
20180296643
2018-10-18

SDF-1 FOR ANAL AND SPHINCTER WOUND HEALING

#61
20180214612
2018-08-02

Three-dimensional tissue scaffold with stem cell attracting element and use thereof

#62
20180214518
2018-08-02

NAP-2 polypeptides and methods for modulating immune system activity in heart tissue

#63
20180142211
2018-05-24

METHODS OF MESENCHYMAL STEM CELL MOBILIZATION AND EXPANSION

#64
20180119155
2018-05-03

Generating targeted sequence diversity in fusion proteins

#65
20180024140
2018-01-25

Atomic description of immune complex that causes heparin-induced thrombocytopenia

#66
20170354720
2017-12-14

Class of therapeutic protein based molecules

#67
20170327554
2017-11-16

Chemokine-cytokine fusion proteins of SDF-1 and CD40L

#68
20170290893
2017-10-12

Treatment of infection by human enterovirus D68

#69
20170275347
2017-09-28

METHODS FOR IDENTIFYING PATIENTS RESPONSIVE TO ANTI-PD-L1 ANTIBODY THERAPY

#70
20170044493
2017-02-16

Method for inducing ectodermal differentiation of embryoid bodies derived from human pluripotent stem cells by CXCR2 stimulation

#71
20160375100
2016-12-29

Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

#72
20160368995
2016-12-22

IDENTIFICATION OF CXCR8, A NOVEL CHEMOKINE RECEPTOR

#73
20160368959
2016-12-22

Surface-binding peptide

#74
20160318984
2016-11-03

Peptide for promoting osteogenic differentiation or vascularization and use thereof

#75
20160229900
2016-08-11

ENGINEERED CXCL12 ALPHA LOCKED DIMER POLYPEPTIDE

#76
20160206697
2016-07-21

Using nucleic acids encoding NAP-2 and TGF-alpha polypeptides to improve cardiac function

#77
20160184407
2016-06-30

Class of therapeutic protein based molecules

#78
20160159928
2016-06-09

Humanized antibodies with ultralong complementary determining regions

#79
20150266951
2015-09-24

Epitope of IP-10 and antibody to same

#80
20150240243
2015-08-27

Generating targeted sequence diversity in fusion proteins

#81
20150104866
2015-04-16

IP-10 antibodies and their uses

#82
20140286925
2014-09-25

Suppression of cancer

#83
20140199304
2014-07-17

Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

#84
20140186376
2014-07-03

Compositions and Methods for Inhibiting CCL3

#85
20130316944
2013-11-28

Engineered CXCL12 alpha locked dimer polypeptide

#86
20130312127
2013-11-21

Efficient sterilization of fish by disruption of germ cell development

#87
20130171095
2013-07-04

Heterodimeric human IgG1 polypeptides with isoelectric point modifications

#88
20130053319
2013-02-28

Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments

#89
20130034523
2013-02-07

Use of SDF-1 to mitigate scar formation

#90
20120230998
2012-09-13

IP-10 antibodies and their uses

#91
20120157384
2012-06-21

Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity

#92
20120053119
2012-03-01

THERAPEUTIC METHOD FOR INCREASING PANCREATIC BETA CELL MASS

#93
20120052043
2012-03-01

Chemokine-Chaperone Fusion Proteins

#94
20110262423
2011-10-27

SUPPRESSION OF CANCER

#95
20110230422
2011-09-22

PURGING OF AN EX VIVO HEMATOPOIETIC STEM CELL CULTURE OF CANCER CELLS

#96
20110224139
2011-09-15

Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage

#97
20110182875
2011-07-28

Class of therapeutic protein based molecules

#98
20110118193
2011-05-19

TREATMENT OF LIQUID CANCERS

#99
20110091410
2011-04-21

Engineered CXCL12 alpha locked dimer polypeptide

#100
20110034383
2011-02-10

CXCL12 GAMMA A CHEMOKINE AND USES THEREOF

#101
20110020375
2011-01-27

Antibodies to stromal cell-derived factor-1 polypeptides

#102
20110002885
2011-01-06

METHODS OF USING ISOLATED RECOMBINANT POLYPEPTIDE ANTAGONISTS OF SDF-1

#103
20100298218
2010-11-25

Single branch heparin-binding growth factor analogs

#104
20100298203
2010-11-25

SDF-I-BASED GLYCOSAMINOGLYCAN ANTAGONISTS AND METHODS OF USING SAME

#105
20100279333
2010-11-04

Methods of screening for compounds that modulate the activity of ADEC, a chemokine expressed in inflamed adenoid

#106
20100272679
2010-10-28

COMPOSITIONS AND METHODS OF PROMOTING WOUND HEALING

#107
20100261202
2010-10-14

Method for efficient production of monocyte-derived multipotent cell (MOMC)

#108
20100196406
2010-08-05

Method of suppressing disease severity of multiple sclerosis using chemokine CXC11

#109
20100077497
2010-03-25

IP-10 antibodies and their uses

#110
20100068763
2010-03-18

MAMMALIAN CHEMOKINES; RECEPTORS; REAGENTS; USES

#111
20100062009
2010-03-11

Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use

#112
20100040603
2010-02-18

Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies

#113
20090305984
2009-12-10

Engineered CXCL12 α locked dimer polypeptide

#114
20090270318
2009-10-29

Method of treatment using high-affinity antagonists of ELR-CXC chemokines

#115
20090192082
2009-07-30

CXCR4 ANTAGONIST TREATMENT OF HEMATOPOIETIC CELLS

#116
20090148936
2009-06-11

LENTIVIRAL VECTOR-MEDIATED GENE TRANSFER AND USES THEREOF

#117
20090148507
2009-06-11

Chimeric polypeptides containing chemokine domains

#118
20090036370
2009-02-05

Leukocyte Adhesion Inhibitor-1 (LAI-1)

#119
20090035318
2009-02-05

METHOD AND COMPOSITION FOR INCREASING THE ENGRAFTMENT EFFICIENCY OF STEM CELLS

#120
20090011981
2009-01-08

Novel Inhibitors of Angiogenesis

#121
20090010946
2009-01-08

Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use

#122
20080319165
2008-12-25

Nucleic acid molecule comprising a nucleic acid sequence coding for a chemokine, a neuropeptide precursor, or at least one neuropeptide

#123
20080318855
2008-12-25

DNA ENCODING FOR RECOMBINANT POLYPEPTIDE EMUTANTS OF HUMAN STROMAL CELL-DERIVED FACTOR 1

#124
20080317756
2008-12-25

Antibodies to Chemokine Alpha-5

#125
20080305041
2008-12-11

Pf4 Pharmacophores and Their Uses

#126
20080261880
2008-10-23

Synthetic approach to designed chemical structures

#127
20080227696
2008-09-18

Single branch heparin-binding growth factor analogs

#128
20080206136
2008-08-28

Binding peptidomimetics and uses of the same

#129
20080193426
2008-08-14

MIGRATION OF HEMATOPOIETIC STEM CELLS AND PROGENITOR CELLS TO THE LIVER

#130
20080138346
2008-06-12

Methods of treatment with anitbodies to a chemokine expressed in inflamed adenoid

#131
20080107643
2008-05-08

MAMMALIAN CHEMOKINES; RECEPTORS; REAGENTS; USES

#132
20070172446
2007-07-26

Synthetic chemokine receptor ligands and methods of use thereof

#133
20070160574
2007-07-12

Design of CXC chemokine analogs for the treatment of human diseases

#134
20070160570
2007-07-12

Chimeric polypeptides containing chemokine domains

#135
20070142269
2007-06-21

NAP derivatives

#136
20070116669
2007-05-24

Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases

#137
20070031392
2007-02-08

Delivery vehicle for recombinant proteins

#138
20070031368
2007-02-08

Chemokine conjugates

#139
20060269993
2006-11-30

DNAXCCR10

#140
20060251616
2006-11-09

Migration of hematopoietic stem cells and progenitor cells to the liver

#141
20060234925
2006-10-19

Embryo implantation inhibitor

#142
20060204498
2006-09-14

Antagonists of cxcr3-binding cxc chemokines

#143
20060183191
2006-08-17

Synthetic approach to designed chemical structures

#144
20060073114
2006-04-06

Compounds and methods to inhibit or augment an inflammatory response

#145
20060062765
2006-03-23

Lentiviral vector-mediated gene transfer and uses thereof

#146
20060035337
2006-02-16

Polynucleotides encoding leukocyte adhesion inhibitor-1 (LAI-1)

#147
20060014682
2006-01-19

CXCR4 antagonist treatment of hematopoietic cells

#148
20060008882
2006-01-12

Antibodies to Chemokine Alpha-5

#149
20050208591
2005-09-22

Antibodies to chemokine Alpha-6

#150
20050191293
2005-09-01

IP-10 antibodies and their uses

#151
20050152871
2005-07-14

Migration of hematopoietic stem cells and progenitor cells to the liver

#152
20050042635
2005-02-24

Prophylactic and therapeutic benefits of a new class of immune stimulating peptides

#153
20050031593
2005-02-10

Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes

#154
20050020528
2005-01-27

Chemokines with amino-terminal modifications

#155
20050019834
2005-01-27

Methods of making chemokine alpha 3 antibodies